Ferriprox for sickle cell – pro

FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. The approval in second line is reasonable both because the studies for approval were done in second line and because Ferroprox may be inferior to Exjade in first line (Cemak et al). This is not an innocuous drug; the most serious side effect seen in about

Read more
Transfusing Young Anemic Women: A Careful Assessment is Required – pro

Anemia is common in young women and is usually due to iron deficiency. If anemia has a slower, subacute onset, younger patients without medical problems can tolerate low hemoglobin levels. Often times, however, in addition to subacute or chronic iron deficiency anemia young women can have anemia of acute blood loss. In this situation there is less time for the body to become habituated to the low red cell levels and a moderately low hemoglobin may

Read more